Integrating NGS Proteomics with Genomics to Improve Immunotherapy Outcomes in Oncology

Explore how next-generation sequencing (NGS) proteomics combined with genomics can enhance immunotherapy outcomes in cancer treatment through this 36-minute webinar. Discover the critical role of predictive and prognostic biomarkers in improving cancer therapy by examining a Phase III clinical trial that utilized the Olink® Explore 3072 proteomics platform to identify a unique 15-protein signature for predicting patient response to chemotherapy treatment. Learn how patients with higher signature scores demonstrated longer survival and improved treatment outcomes, while integrated genomics data revealed gene mutations and pathways correlated with enhanced treatment response. Understand how multiomics approaches can improve clinical trial decision-making in oncology, specifically focusing on how proteomics and genomics identify predictive and prognostic biomarkers to improve immunotherapy outcomes in small cell lung cancer. Gain insights into how CLIA/CAP/ISO15189-certified multiomics services can support high-impact biomarker research in oncology clinical trials, providing practical knowledge for implementing these advanced analytical approaches in cancer research and treatment optimization.